Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
Abstract Backround We describe one of the first cases of a Posterior reversible encephalopathy syndrome (PRES) under tocilizumab as treatment of Giant cell arteritis (GCA). Case presentation A 65-year-old female with known GCA and treatment with Tocilizumab (TCZ) developed a convulsive epileptic sei...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-06-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-021-02231-7 |
| id |
doaj-9c215b3ed2194618ae302ad4c0aeffdd |
|---|---|
| record_format |
Article |
| spelling |
doaj-9c215b3ed2194618ae302ad4c0aeffdd2021-06-27T11:23:41ZengBMCBMC Neurology1471-23772021-06-012111310.1186/s12883-021-02231-7Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case reportMichaela Butryn0Sabine Mewes1Eugen Feist2Oliver Beuing3Christian Müller4Jens Neumann5Institute of Cognitive Neurology and Dementia Research, Otto von Guericke University MagdeburgDepartment of Rheumatology, |Helios clinicDepartment of Rheumatology, |Helios clinicDepartment of Radiology, Otto von Guericke University MagdeburgDepartment of Gastroenterology, Hepatology und Infectiology, Otto von Guericke University MagdeburgDepartment of Neurology, Otto von Guericke University MagdeburgAbstract Backround We describe one of the first cases of a Posterior reversible encephalopathy syndrome (PRES) under tocilizumab as treatment of Giant cell arteritis (GCA). Case presentation A 65-year-old female with known GCA and treatment with Tocilizumab (TCZ) developed a convulsive epileptic seizure for the first time. MRI was suggestive of PRES and an associated left sided occipital hemorrhage. Extensive high blood pressure values were not detected. The patient recovered within a week and no further seizures occurred under anticonvulsive medication. Conclusion PRES during the treatment with Tocilizumab hasn’t been described in GCA so far. There are single reports of an association between TCZ and PRES in other entities. Thus, a link between interleukin-6 and the integrity of the vasculature could be considered. The clinical consequence should be a stringent blood pressure monitoring in the ambulant setting of patients receiving TCZ.https://doi.org/10.1186/s12883-021-02231-7TocilizumabPosterior reversible encephalopathy syndromeGiant cell arteritis |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Michaela Butryn Sabine Mewes Eugen Feist Oliver Beuing Christian Müller Jens Neumann |
| spellingShingle |
Michaela Butryn Sabine Mewes Eugen Feist Oliver Beuing Christian Müller Jens Neumann Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report BMC Neurology Tocilizumab Posterior reversible encephalopathy syndrome Giant cell arteritis |
| author_facet |
Michaela Butryn Sabine Mewes Eugen Feist Oliver Beuing Christian Müller Jens Neumann |
| author_sort |
Michaela Butryn |
| title |
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report |
| title_short |
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report |
| title_full |
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report |
| title_fullStr |
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report |
| title_full_unstemmed |
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report |
| title_sort |
tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report |
| publisher |
BMC |
| series |
BMC Neurology |
| issn |
1471-2377 |
| publishDate |
2021-06-01 |
| description |
Abstract Backround We describe one of the first cases of a Posterior reversible encephalopathy syndrome (PRES) under tocilizumab as treatment of Giant cell arteritis (GCA). Case presentation A 65-year-old female with known GCA and treatment with Tocilizumab (TCZ) developed a convulsive epileptic seizure for the first time. MRI was suggestive of PRES and an associated left sided occipital hemorrhage. Extensive high blood pressure values were not detected. The patient recovered within a week and no further seizures occurred under anticonvulsive medication. Conclusion PRES during the treatment with Tocilizumab hasn’t been described in GCA so far. There are single reports of an association between TCZ and PRES in other entities. Thus, a link between interleukin-6 and the integrity of the vasculature could be considered. The clinical consequence should be a stringent blood pressure monitoring in the ambulant setting of patients receiving TCZ. |
| topic |
Tocilizumab Posterior reversible encephalopathy syndrome Giant cell arteritis |
| url |
https://doi.org/10.1186/s12883-021-02231-7 |
| work_keys_str_mv |
AT michaelabutryn tocilizumabassociatedposteriorreversibleencephalopathysyndromeingiantcellarteritiscasereport AT sabinemewes tocilizumabassociatedposteriorreversibleencephalopathysyndromeingiantcellarteritiscasereport AT eugenfeist tocilizumabassociatedposteriorreversibleencephalopathysyndromeingiantcellarteritiscasereport AT oliverbeuing tocilizumabassociatedposteriorreversibleencephalopathysyndromeingiantcellarteritiscasereport AT christianmuller tocilizumabassociatedposteriorreversibleencephalopathysyndromeingiantcellarteritiscasereport AT jensneumann tocilizumabassociatedposteriorreversibleencephalopathysyndromeingiantcellarteritiscasereport |
| _version_ |
1721357912210669568 |